SHC — Sotera Health Company stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

17.99

+0.13+0.73%

Overview Short InterestFilings

SHCQT67Sotera Health Company·NASDAQ

Overview Short InterestFilings

17.99+0.73%

Loading chart...

Screen all →

RDNT+4.74%$66.80 TWST+10.39%$101.06 BLLN-0.92%$137.32 VCYT-3.17%$44.85 QGEN+2.25%$42.33 NEOG-1.16%$11.90 CRL-0.71%$230.87 CDNA+9.47%$47.85

Snapshot

Index	-	P/E	43.42	EPS (ttm)	0.41	Insider Own	-	Shs Outstand	285.17M	Perf Week	2.94%

Market Cap	5.09B	Forward P/E	16.85	EPS next Y	1.06	Insider Trans	-30.17%	Shs Float	154.14M	Perf Month	0.62%

Enterprise Value	7.05B	PEG	0.12	EPS next Q	-	Inst Own	-	Short Float	10.27%	Perf Quarter	14.78%

Income	118.16M	P/S	4.28	EPS this Y	135.81%	Inst Trans	-	Short Ratio	4.87	Perf Half Y	-2.51%

Sales	1.19B	P/B	8.17	EPS next Y	9.62%	ROA	3.64%	Short Interest	15.84M	Perf YTD	1.25%

Book/sh	-	P/C	19.49	EPS next 5Y	9.23%	ROE	20.57%	52W High	20.00 -10.03%	Perf Year	49.83%

Cash/sh	-	P/FCF	52.59	EPS past 3/5Y	-	ROIC	7.96%	52W Low	11.08 62.36%	Perf 3Y	-6.00%

Dividend Est.	-	EV/EBITDA	14.42	Sales past 3/5Y	5.05% 7.31%	Gross Margin	55.01%	Volatility	2.76% 2.81%	Perf 5Y	-21.63%

Dividend TTM	-	EV/Sales	5.93	EPS Y/Y TTM	156.25%	Oper. Margin	35.52%	ATR (14)	0.50	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.52	Sales Y/Y TTM	8.00%	Profit Margin	9.91%	RSI (14)	56.72	Recom	2.08

Dividend Gr. 3/5Y	-	Current Ratio	2.82	EPS Q/Q	28.57%	SMA20	0.49%	Beta	1.74	Target Price	19.00

Payout	0.00%	Debt/Eq	3.65	Sales Q/Q	9.80%	SMA50	6.21%	Rel Volume	0.45	Prev Close	17.86

Employees	3,000	LT Debt/Eq	3.71	Earnings	Aug 06	SMA200	8.36%	Avg Volume	3.38M	Price	17.99

IPO Date	Nov 20, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.36% 3.42%	Net Debt/EBITDA	4.00	Volume	1,514,719	Change	0.73%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-24-26	Reiterated	UBS		$18 → $19
Jun-05-26	Reiterated	Goldman Sachs	Buy	$17 → $20
Apr-14-26	Reiterated	Barclays	Overweight	$20 → $18
Jan-09-26	Upgrade	Piper Sandler	Neutral → Overweight	$17 → $24
Jan-08-26	Reiterated	RBC Capital	Outperform	$17 → $24
Nov-05-25	Reiterated	Barclays	Overweight	$19 → $20
Nov-05-25	Reiterated	Piper Sandler	Neutral	$13 → $17
Oct-02-25	Reiterated	Barclays	Overweight	$17 → $19
May-05-25	Upgrade	Goldman Sachs	Neutral → Buy	$8.00 → $17
Dec-05-24	Reiterated	Jefferies	Buy	$18 → $15

Latest News

Jul-31-26

Jul-31-2604:13AM

Dimensional Fund Advisors LP Buys 358,281 Shares of Sotera Health Company $SHCdefenseworld.net

Jul-30-26

Jul-30-2604:45AM

Bank of New York Mellon Corp Acquires 166,055 Shares of Sotera Health Company $SHCdefenseworld.net

Jul-28-26

Jul-28-2602:40PM

What Makes Sotera Health (SHC) a Strong Position in Your Portfolio?Yahoo

Jul-24-26

Jul-24-2609:45AM

2 Cash-Producing Stocks with Competitive Advantages and 1 We Brush OffYahoo

Jul-23-26

Jul-23-2607:00AM

Sotera Health Announces Second-Quarter 2026 Earnings Release Dateglobenewswire.com

Jul-17-26

Jul-17-2602:01PM

3 Small-Cap Stocks That Fall ShortYahoo

Jul-07-26

Jul-07-2601:05PM

3 Reasons SHC is Risky and 1 Stock to Buy InsteadYahoo

Jun-24-26

Jun-24-2610:45AM

Barclays Maintains Overweight on Sotera Health, Raises Price Target to $19Benzinga

Jun-16-26

Jun-16-2602:09PM

1 Healthcare Stock for Long-Term Investors and 2 We Turn DownYahoo

Company

Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	1,188	1,164	1,100	1,049	1,004	931	818	778	746
Cost of Goods Sold Incl. D&A	536	518	498	472	447	413	375	383	389
Gross Profit	655	646	602	577	557	519	444	395	357
Selling, General and Administrative Excl. Other	247	253	243	237	246	198	179	147	133
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	-16	0	62	63	63	64	59	65	58
Operating Income	422	393	298	277	248	257	206	184	81
Interest Expense	150	156	165	143	80	74	215	158	143
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-68	-90	-19	-28	-411	-7	-30	-27	87
Net Income Before Taxes	205	148	114	106	-243	176	-39	-1	24
Income Taxes	88	70	69	55	-10	59	-1	20	30
Consolidated Net Income	118	78	44	51	-234	117	-39	-21	-6
Net Income From Continuing Operations	118	78	44	51	-234	117	-37	-20	-6
Net Income	118	78	44	51	-234	117	-39	-21	-6
EPS (Recurring)	0.41	0.27	0.16	0.18	-0.83	0.41	-0.14	-0.07	-0.02
EPS (Basic, Before Extraordinaries)	0.41	0.27	0.16	0.18	-0.83	0.41	-0.14	-0.07	-0.02
EPS (Diluted)	0.41	0.27	0.16	0.18	-0.83	0.41	-0.14	-0.07	-0.02
EBITDA	488	442	442	407	-17	401	320	304	314
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	43.88	65.33	85.50	93.61	—	57.44	—	—	—
Price To Sales Ratio	4.32	4.30	3.52	4.51	2.32	7.06	9.49	—	—
Gross Margin	55.13	55.50	54.73	55.00	55.48	55.75	54.28	50.77	47.86
Operating Margin	35.52	33.76	27.09	26.41	24.70	27.60	25.18	23.65	10.86
Net Margin	9.93	6.70	4.00	4.86	-23.31	12.57	-4.77	-2.70	-0.80
Shares Outstanding	285	284	283	281	280	279	283	284	246
Market Capitalization	5,127	5,010	3,871	4,735	2,332	6,570	7,766	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WARBURG PINCUS & CO.	director, 10 percent owner:	May 13 '26	Sale	15.17	19,102,952	289,753,576	0	May 15
GTCR INVESTMENT XI LLC	director, 10 percent owner:	May 13 '26	Sale	15.17	12,735,301	193,169,046	0	May 15
GTCR INVESTMENT XI LLC	director, 10 percent owner:	Mar 06 '26	Sale	15.27	10,000,000	152,700,000	12,735,301	Mar 10
WARBURG PINCUS & CO.	director, 10 percent owner:	Mar 06 '26	Sale	15.27	15,000,000	229,050,000	19,102,952	Mar 10
Petras Michael B. Jr.	Chairman & CEO	Mar 02 '26	Option Exercise	0.00	89,686	0	570,835	Mar 04
DIMITRIEF ALEXANDER	SVP, General Counsel and Sec.	Mar 02 '26	Option Exercise	0.00	16,816	0	343,600	Mar 04
Lyons Jonathan M.	Sr. Vice President, CFO	Mar 02 '26	Option Exercise	0.00	17,937	0	201,493	Mar 04
Rutz Michael P	President of Sterigenics	Mar 02 '26	Option Exercise	0.00	14,573	0	456,553	Mar 04
Petras Michael B. Jr.	Chairman & CEO	Dec 08 '25	Sale	16.45	750,000	12,337,499	0	Dec 10
WARBURG PINCUS & CO.	director, 10 percent owner:	Dec 03 '25	Sale	16.33	9,720,000	158,727,600	34,102,952	Dec 05
GTCR INVESTMENT XI LLC	director, 10 percent owner:	Dec 03 '25	Sale	16.33	6,480,000	105,818,400	22,735,301	Dec 05
GTCR INVESTMENT XI LLC	director, 10 percent owner:	Nov 10 '25	Sale	15.65	12,000,000	187,812,000	29,215,301	Nov 12
WARBURG PINCUS & CO.	director, 10 percent owner:	Nov 10 '25	Sale	15.65	18,000,000	281,718,000	43,822,952	Nov 12
GTCR INVESTMENT XI LLC	director, 10 percent owner:	Sep 05 '25	Sale	15.11	8,000,000	120,888,000	41,215,301	Sep 09
WARBURG PINCUS & CO.	director, 10 percent owner:	Sep 05 '25	Sale	15.11	12,000,000	181,332,000	61,822,952	Sep 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.